- 1501. gp100 Antigen/Incomplete Freund's Adjuvant/MART-1 Antigen/Tyrosinase Peptide
- (UMLS (NCI) C0677810) =Therapeutic or Preventive Procedure
| - 1551. Gracilis
- (UMLS (NCI) C0224439) =Body Part, Organ, or Organ Component
|
- 1502. gp100 Antigen/Incomplete Freund's Adjuvant/Sargramostim/Tyrosinase Peptide
- (UMLS (NCI) C0796681) =Therapeutic or Preventive Procedure
| - 1552. GRACILIS MUSC TRANSPLAN
- [ ] (UMLS (ICD9CM) C0193219) =Therapeutic or Preventive Procedure
|
- 1503. gp100 Antigen/Incomplete Freund's Adjuvant/Tyrosinase Peptide
- (UMLS (NCI) C0678070) =Therapeutic or Preventive Procedure ;
| - 1553. Grade
- [A position on a scale of intensity or amount or quality. ( NCI )] (UMLS (NCI) C0441800) =Classification
|
- 1504. gp100 Antigen/Interferon Alfa/MART-1 Antigen/Montanide ISA-51/Sargramostim/Tyrosinase Peptide
- (UMLS (NCI) C0935703) =Therapeutic or Preventive Procedure
| - 1554. grade
- [A system for classifying cancer cells in terms of how abnormal they appear when examined under a microscope. The objective of a grading system is to provide information about the probable growth rate of the tumor and its tendency to spread. The systems used to grade tumors vary with each type of cancer. Grading plays a role in treatment decisions. ( NCI )] (UMLS (NCI) C0919553) grading;
Histologic Grade;
Histopathologic Grade;
Histopathology Grade;
=Classification ;
|
- 1505. gp100 Antigen/Interferon Alfa/MART-1 Antigen/Montanide ISA-51/Tyrosinase Peptide
- (UMLS (NCI) C0935704) =Therapeutic or Preventive Procedure
| - 1555. Grade 1 Clear Cell Renal Cell Carcinoma
- (UMLS (NCI) C1333829) Grade 1 Conventional (Clear Cell) Renal Cell Carcinoma;
=Neoplastic Process ;
|
- 1506. gp100 Antigen/Interleukin-12/MART-1 Antigen/Montanide ISA-51/Sargramostim/Tyrosinase Peptide
- (UMLS (NCI) C1134585) =Therapeutic or Preventive Procedure ;
| - 1556. Grade 1 Conjunctival Intraepithelial Neoplasia
- (UMLS (NCI) C1334421) Grade I Conjunctival Intraepithelial Neoplasia;
Low Grade Conjunctival Intraepithelial Neoplasia;
=Neoplastic Process |
- 1507. gp100 Antigen/Interleukin-12/Montanide ISA-51
- (UMLS (NCI) C0879318) =Therapeutic or Preventive Procedure
| - 1557. Grade 1 Corneal Intraepithelial Neoplasia
- (UMLS (NCI) C1334422) Grade I Corneal Intraepithelial Neoplasia;
Low Grade Corneal Intraepithelial Neoplasia;
=Neoplastic Process |
- 1508. gp100 Antigen/Interleukin-12/Montanide ISA-51/Tyrosinase Peptide
- (UMLS (NCI) C0879306) =Therapeutic or Preventive Procedure
| - 1558. Grade 1 Cutaneous Follicular Lymphoma
- (UMLS (NCI) C1333830) =Neoplastic Process ;
|
- 1509. gp100 Antigen/Interleukin-2
- (UMLS (NCI) C0281723) =Therapeutic or Preventive Procedure
| - 1559. Grade 1 Diffuse Follicle Centre Lymphoma
- (UMLS (NCI) C1333831) =Neoplastic Process ;
|
- 1510. gp100 Antigen/interleukin-2/MART-1 Antigen
- (UMLS (NCI) C0392986) =Therapeutic or Preventive Procedure
| - 1560. Grade 1 Glandular Intraepithelial Neoplasia
- (UMLS (NCI) C1334423) Grade I Glandular Intraepithelial Neoplasia;
Low Grade Glandular Intraepithelial Neoplasia;
=Neoplastic Process |
- 1511. gp100 Antigen/Interleukin-2/MART-1 Antigen/Montanide ISA-51
- (UMLS (NCI) C0879299) =Therapeutic or Preventive Procedure
| - 1561. Grade 1 Intraepithelial Neoplasia
- (UMLS (NCI) C0334058) =Cell or Molecular Dysfunction
|
- 1512. gp100 Antigen/Interleukin-2/MART-1 Antigen/Montanide ISA-51/Tyrosinase Peptide
- (UMLS (NCI) C0879325) =Therapeutic or Preventive Procedure
| - 1562. Grade 1 Lesion
- (UMLS (NCI) C1333833) =Finding ;
|
- 1513. gp100 Antigen/Interleukin-2/Montanide ISA-51
- (UMLS (NCI) C0879311) =Therapeutic or Preventive Procedure
| - 1563. Grade 1 Malignant Neoplasm
- (UMLS (NCI) C1333834) =Neoplastic Process ;
|
- 1514. gp100 Antigen/Interleukin-2/Montanide ISA-51/Tumor Infiltrating Lymphocytes
- (UMLS (NCI) C0879363) =Therapeutic or Preventive Procedure ;
| - 1564. Grade 1 Pancreatic Intraepithelial Neoplasia
- (UMLS (NCI) C1333869) Grade I Pancreatic Intraepithelial Neoplasia;
=Neoplastic Process |
- 1515. gp100 Antigen/MAGE-3/MART-1 Antigen/Tyrosinase Peptide
- (UMLS (NCI) C0796513) =Therapeutic or Preventive Procedure
| - 1565. Grade 1 Penile Intraepithelial Neoplasia
- (UMLS (NCI) C1334427) Grade I Penile Intraepithelial Neoplasia;
Low Grade Penile Intraepithelial Neoplasia;
=Neoplastic Process |
- 1516. gp100 Antigen/MART-1 Antigen
- (UMLS (NCI) C0392993) =Therapeutic or Preventive Procedure
| - 1566. Grade 1 PIN
- [Prostatic intraepithelial neoplasia characterized by the proliferation of secretory cells with irregular spacing in the ducts and acini. Although some proliferating epithelial cells may contain prominent nucleoli, the cytologic atypia and architectural growth patterns that are seen in the high grade prostatic intraepithelial neoplasia are absent. The presence of low grade prostatic intraepithelial neoplasia in needle biopsy is not a risk factor for the subsequent detection of carcinoma on repeat biopsy.. ( NCI )] (UMLS (NCI) C1168328) Grade 1 Prostatic Intraepithelial Neoplasia;
Grade I PIN;
Grade I Prostatic Intraepithelial Neoplasia;
Low Grade Prostatic Intraepithelial Neoplasia;
Low-Grade Intraepithelial Neoplasia of Prostate;
Low-Grade Intraepithelial Neoplasia of the Prostate;
Low-Grade PIN;
PIN-1;
=Neoplastic Process |
- 1517. gp100 Antigen/MART-1 Antigen/Montanide ISA-51
- (UMLS (NCI) C0879298) =Therapeutic or Preventive Procedure
| - 1567. Grade 1 Squamous Intraepithelial Neoplasia
- (UMLS (NCI) C1302773) Grade I Squamous Intraepithelial Neoplasia;
Low Grade Squamous Intraepithelial Neoplasia;
Low-Grade Squamous Intraepithelial Lesion;
LSIL;
=Neoplastic Process |
- 1518. gp100 Antigen/MART-1 Antigen/Montanide ISA-51/Sargramostim/Tyrosinase Peptide
- (UMLS (NCI) C0879326) =Therapeutic or Preventive Procedure
| - 1568. Grade 1 Vaginal Intraepithelial Neoplasia
- (UMLS (NCI) C0349554) =Neoplastic Process
|
- 1519. gp100 Antigen/MART-1 Antigen/Montanide ISA-51/Tyrosinase Peptide
- (UMLS (NCI) C0879324) =Therapeutic or Preventive Procedure
| - 1569. Grade 1 VIN
- (UMLS (NCI) C0495106) =Neoplastic Process ;
|
- 1520. gp100 Antigen/MART-1 Antigen/Tyrosinase Peptide
- (UMLS (NCI) C0879342) =Therapeutic or Preventive Procedure
| - 1570. Grade 2 Clear Cell Renal Cell Carcinoma
- (UMLS (NCI) C1333835) Grade 2 Conventional (Clear Cell) Renal Cell Carcinoma =Neoplastic Process ;
|
- 1521. gp100 Antigen/Montanide ISA-51
- (UMLS (NCI) C0879313) =Therapeutic or Preventive Procedure
| - 1571. Grade 2 Cutaneous Follicular Lymphoma
- (UMLS (NCI) C1333836) =Neoplastic Process ;
|
- 1522. gp100 Antigen/Montanide ISA-51/Sargramostim
- (UMLS (NCI) C0879319) =Therapeutic or Preventive Procedure
| - 1572. Grade 2 Diffuse Follicle Centre Lymphoma
- (UMLS (NCI) C1333837) =Neoplastic Process ;
|
- 1523. gp100 Antigen/Montanide ISA-51/Sargramostim/Tetanus Peptide Melanoma Vaccine/Tyrosinase Peptide
- (UMLS (NCI) C0879307) =Therapeutic or Preventive Procedure
| - 1573. Grade 2 Glandular Intraepithelial Neoplasia
- (UMLS (NCI) C1333861) Grade II Glandular Intraepithelial Neoplasia;
Moderate Glandular Dysplasia =Neoplastic Process |
- 1524. gp100 Antigen/Montanide ISA-51/Sargramostim/Tyrosinase Peptide
- (UMLS (NCI) C0879329) =Therapeutic or Preventive Procedure
| - 1574. Grade 2 Infiltrating Breast Carcinoma
- (UMLS (NCI) C1333838) Grade 2 Invasive Breast Carcinoma;
Intermediate Combined Histologic Grade Infiltrating Breast Carcinoma;
Moderately Differentiated Infiltrating Breast Carcinoma;
Moderately Differentiated Invasive Breast Carcinoma;
Moderately Favorable Infiltrating Breast Carcinoma =Neoplastic Process ;
|
- 1525. gp100 Antigen/Montanide ISA-51/Tyrosinase Peptide
- (UMLS (NCI) C0879297) =Therapeutic or Preventive Procedure
| - 1575. Grade 2 Intraepithelial Neoplasia
- (UMLS (NCI) C0334059) =Cell or Molecular Dysfunction
|
- 1526. gp100 Antigen/QS21/Tyrosinase Peptide
- (UMLS (NCI) C0678089) =Therapeutic or Preventive Procedure
| - 1576. Grade 2 Lesion
- (UMLS (NCI) C1333839) =Finding
|
- 1527. gp100 Antigen/Sargramostim/Tyrosinase Peptide
- (UMLS (NCI) C0678090) =Therapeutic or Preventive Procedure
| - 1577. Grade 2 Malignant Neoplasm
- (UMLS (NCI) C1333840) =Neoplastic Process
|
- 1528. gp100 Antigen/Tetanus Peptide Melanoma Vaccine/Tyrosinase Peptide
- (UMLS (NCI) C0879347) =Therapeutic or Preventive Procedure
| - 1578. Grade 2 Nodular Sclerosis Hodgkin Lymphoma
- (UMLS (NCI) C0334630) =Neoplastic Process
|
- 1529. gp100 Antigen/Tyrosinase Peptide
- (UMLS (NCI) C0678047) =Therapeutic or Preventive Procedure ;
| - 1579. Grade 2 Pancreatic Intraepithelial Neoplasia
- (UMLS (NCI) C0586364) =Disease or Syndrome
|
- 1530. gp120
- [glycoprotein encoded by HIV envelope gene (env) with a molecular weight of 120,000; interaction between gp120 and CD4 on T-helper cells is involved in the recognition of the cells by HIV and the binding of HIV to those cells. ( CSP )] (UMLS (CSP) C0019691) =Amino Acid, Peptide, or Protein; Biologically Active Substance =HIV envelope protein;
| - 1580. Grade 2 Penile Intraepithelial Neoplasia
- (UMLS (NCI) C1333863) Grade II Penile Intraepithelial Neoplasia;
=Neoplastic Process |
- 1531. GP145-TRKC
- [Widely expressed (mainly nervous tissue) by human NTRK3 Gene (IR Tyr Kinase Family) as alternative isoforms A (839-aa 94-kDa precursor), B (612-aa), C (825-aa), and D (830-aa), Neurotrophic Tyrosine Kinase Receptor Type 3 is a type I membrane receptor for NTF3 containing 2 LRR repeats and 2 Ig-like C2-type domains. Monomeric (low affinity) and dimeric (high affinity) forms appear to exist in dynamic equilibrium and the isoforms do not have identical signaling properties. Known substrates for TRK receptors are SHC, PI-3 kinase, and PLC-gamma-1. NTRK3 undergoes ligand-mediated auto-phosphorylation. (NCI) ( NCI )] (UMLS (NCI) C0132300) =Amino Acid, Peptide, or Protein; Enzyme; Receptor
| - 1581. Grade 2 Squamous Intraepithelial Lesion
- (UMLS (NCI) C1302798) Grade 2 Squamous Intraepithelial Neoplasia;
Grade II Squamous Intraepithelial Lesion;
Grade II Squamous Intraepithelial Neoplasia =Neoplastic Process |
- 1532. gp160
- [glycoprotein encoded by HIV envelope gene (env) with a molecular weight of 160,000 daltons. ( CSP )] (UMLS (CSP) C0062790) =Amino Acid, Peptide, or Protein; Biologically Active Substance ;
=HIV envelope protein;
| - 1582. Grade 2 Vaginal Intraepithelial Neoplasia
- (UMLS (NCI) C0349555) =Neoplastic Process
|
- 1533. gp209-2M Antigen/Heat Shock Protein 70/OVA Bip Peptide/Tyrosinase Peptide
- (UMLS (NCI) C0879488) =Therapeutic or Preventive Procedure
| - 1583. Grade 2 VIN
- (UMLS (NCI) C0495107) =Neoplastic Process ;
|
- 1534. gp209-2M Antigen/Incomplete Freund's Adjuvant/Interleukin-2
- (UMLS (NCI) C0796405) gp209-2M/IFA/IL-2;
=Therapeutic or Preventive Procedure | - 1584. Grade 3 Clear Cell Renal Cell Carcinoma
- (UMLS (NCI) C1333841) Grade 3 Conventional (Clear Cell) Renal Cell Carcinoma =Neoplastic Process
|
- 1535. gp209-2M Antigen/Interleukin-2/Montanide ISA-51
- (UMLS (NCI) C0879596) =Therapeutic or Preventive Procedure
| - 1585. Grade 3 Infiltrating Breast Carcinoma
- (UMLS (NCI) C1333843) Grade 3 Invasive Breast Carcinoma;
High Combined Histologic Grade Infiltrating Breast Carcinoma;
Poorly Differentiated Infiltrating Breast Carcinoma;
Poorly Differentiated Invasive Breast Carcinoma;
Unfavorable Infiltrating Breast Carcinoma =Neoplastic Process |
- 1536. GPI-0100
- [A semi-synthetic triterpene glycoside, derived from the naturally occurring saponins. GPI-0100 functions as an adjuvant when given as part of a vaccine preparation to improve the immunogenicity of antigens such as proteins, carbohydrates. GPI-0100 containing vaccines have been used with both viral and tumor antigens to elicit a Type 1 helper T cell response for those diseases in which a cytotoxic T lymphocyte (CTL) response is desired. ( NCI )] (UMLS (NCI) C0935831) =Carbohydrate; Pharmacologic Substance ;
| - 1586. Grade 3 Lesion
- (UMLS (NCI) C1333844) =Finding
|
- 1537. GPI-0100/MUC-2-Globo H-KLH Conjugate Vaccine
- (UMLS (NCI) C0935833) =Therapeutic or Preventive Procedure
| - 1587. Grade 3 Malignant Neoplasm
- (UMLS (NCI) C1333845) =Neoplastic Process
|
- 1538. GPOH-HD 95 Regimen
- [A regimen consisting of vincristine, prednisone, procarbazine and doxorubicin (OPPA) used in combination with radiation therapy for the treatment of female patients with low-risk, childhood Hodgkin's lymphoma. ( NCI )] (UMLS (NCI) C0134006) =Therapeutic or Preventive Procedure ;
| - 1588. Grade 3 Pancreatic Intraepithelial Neoplasia
- [Stage 0: Tis, N0, M0. Tis: Carcinoma in situ. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 6th ed.) - 2003 ( NCI )] (UMLS (NCI) C0586365) =Neoplastic Process
|
- 1539. GPR
- [Rod-shaped bacteria that retain the crystal violet stain when treated by Gram's method. ( NCI )] (UMLS (NCI) C0085498) =Bacterium
| - 1589. Grade 3a
- (UMLS (NCI) C0585112) =Intellectual Product
|
- 1540. GPRC5A
- [Encoded by human RAI3 Gene (GPCR3 Family), 357-aa 40-kDa Retinoic Acid Induced 3 protein contains 7 predicted GPCR-signature transmembrane domains and a potential N-linked glycosylation site. Likely involved in the interaction between retinoid acid and G protein signaling pathways, RAI3 may play a role in embryonic development and epithelial cell differentiation. (NCI) ( NCI )] (UMLS (NCI) C0762318) RAI3;
RAIG1;
Retinoic Acid Induced 3 =Amino Acid, Peptide, or Protein; Receptor | - 1590. Grade 3a Follicular Lymphoma
- (UMLS (NCI) C1333846) =Neoplastic Process
|
- 1541. GPX-100
- [An anticancer drug that belongs to the family of drugs called antitumor antibiotics. It is an anthracycline. ( NCI )] (UMLS (NCI) C0796383) =Organic Chemical; Antibiotic
| - 1591. Grade 3a Lesion
- (UMLS (NCI) C1333847) =Finding
|
- 1542. GQ
- [Island in the North Pacific Ocean, about three-quarters of the way from Hawaii to the Philippines. (NCI) ( NCI )] (UMLS (NCI) C0018309) =Geographic Area ;
| - 1592. Grade 3a Malignant Neoplasm
- (UMLS (NCI) C1333848) =Neoplastic Process
|
- 1543. GR
- [A country in Southern Europe, bordering the Aegean Sea, Ionian Sea, and the Mediterranean Sea, between Albania and Turkey. (NCI) ( NCI )] (UMLS (NCI) C0018226) =Geographic Area ;
| - 1593. Grade 3b
- (UMLS (NCI) C0585113) =Intellectual Product
|
- 1544. GR 117289
- (UMLS (NCI) C0211676) =Organic Chemical; Pharmacologic Substance ;
| - 1594. Grade 3b Follicular Lymphoma
- (UMLS (NCI) C1333849) =Neoplastic Process
|
- 1545. GR 38032F
- (UMLS (NCI) C0733434) =Organic Chemical; Pharmacologic Substance
| - 1595. Grade 3b Lesion
- (UMLS (NCI) C1333850) =Finding
|
- 1546. GR 63178A
- (UMLS (NCI) C0950804) =Organic Chemical; Pharmacologic Substance
| - 1596. Grade 3b Malignant Neoplasm
- (UMLS (NCI) C1333851) =Neoplastic Process
|
- 1547. GR 85548A
- [The hydrochloride salt form of naratriptan, a sulfonamide with selective serotonin (5-HT) 1 receptor agonistic activity and anti-migraine property. Naratriptan hydrochloride binds selectively and with high affinity to the 5-HT1D and 5-HT1B receptor subtypes. Activation of these 5-HT1D/B receptors located on intracranial blood vessels leads to vasoconstriction and provides relief of migraine headaches. Naratriptan hydrochloride may also exerts its effect by stimulation of 5-HT1D/1B receptors on sensory nerve endings in the trigeminal system thereby decreasing the release of pro-inflammatory neuropeptides. ( NCI )] (UMLS (NCI) C0771993) Naratriptan Hydrochloride;
NARATRIPTAN HYDROCHLORIDE PREPARATION;
N-methyl-3-( 1-methyl-4-piperidinyl)-1H-indole-5-ethanesulfonamide Monohydrochloride;
=Organic Chemical; Pharmacologic Substance ;
=NARATRIPTAN;
=NARATRIPTAN HYDROCHLORIDE 1 MG;
NARATRIPTAN HYDROCHLORIDE 2.5 MG;
| - 1597. Grade 4 Clear Cell Renal Cell Carcinoma
- (UMLS (NCI) C1333852) Grade 4 Conventional (Clear Cell) Renal Cell Carcinoma;
=Neoplastic Process |
- 1548. GR-C507/75
- (UMLS (NCI) C0733437) =Organic Chemical; Pharmacologic Substance
| - 1598. Grade 4 Lesion
- (UMLS (NCI) C1333853) =Finding
|
- 1549. GR6
- [Normally expressed in early fetal development by human GR6 Gene, the function of 149-aa 16-kDa Putative GR6 Protein is unknown. (NCI) ( NCI )] (UMLS (NCI) C1308249) GR6 Protein;
Putative GR6 Protein;
=Amino Acid, Peptide, or Protein; Biologically Active Substance | - 1599. Grade 4 Malignant Neoplasm
- (UMLS (NCI) C1333854) =Neoplastic Process
|
- 1550. graafian follicle
- [maturing ovum eccentrically located in a hillock of specialized epithelial cells in the ovary; precursor to the mature ovarian follicle which is ejected during ovulation. ( CSP )] (UMLS (CSP) C0600225) =Body Part, Organ, or Organ Component =Genital System, Female, Ovary;
=Granulosa Cell | - 1600. Grade I Colon Adenocarcinoma
- (UMLS (NCI) C1333866) Well Differentiated Colon Adenocarcinoma;
=Neoplastic Process |
home
